Introduction

Radiation therapy remains one of the three pillars of modern cancer treatment, alongside surgery and chemotherapy, using precisely targeted ionizing radiation to destroy or control the growth of cancer cells. Delivered either externally through linear accelerators or internally through radioactive implants, radiation therapy has evolved dramatically over the past two decades, moving from broad-beam treatment toward highly precise, image-guided, and adaptive techniques like proton therapy, stereotactic radiosurgery, and MR-guided radiotherapy that spare healthy tissue while more effectively targeting tumors.

The global radiotherapy market was valued at approximately USD 7.86 billion in 2025 and is projected to reach USD 12.93 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.73% over the forecast period, according to Intellectual Market Insights Research. This growth reflects the rising global incidence of cancer, expected to reach 24 million new cases annually by 2030 according to the World Health Organization, alongside increasing adoption of advanced, precision-targeted radiation techniques.

The competitive landscape is dominated by a small number of large diversified medical technology and imaging conglomerates, several of which built their radiation oncology businesses through major acquisitions, most notably Siemens Healthineers' 2021 acquisition of Varian Medical Systems, once an independent radiotherapy leader in its own right. Alongside these diversified giants, specialized radiation oncology companies like Elekta and Accuray compete purely on precision radiotherapy technology and clinical software.

Understanding which companies lead this technically sophisticated and clinically vital market is essential for hospital procurement teams, oncology clinicians, and healthcare industry analysts. This article provides a research-based analysis of the top companies in the global radiation therapy market, their positioning, flagship offerings, and the regional and technological forces shaping the competitive landscape.

Market Overview

Why the Radiation Therapy Market Is Growing

1. Rising Global Cancer Incidence

Global cancer cases are expected to reach 24 million annually by 2030 according to the World Health Organization, directly driving demand for radiation therapy as one of the primary treatment modalities used across breast, lung, prostate, and dozens of other cancer types.

2. Increasing Adoption of Precision Radiotherapy Techniques

Advanced techniques including proton therapy, stereotactic body radiotherapy (SBRT), and intensity-modulated radiation therapy (IMRT) are gaining adoption for their ability to precisely target tumors while sparing surrounding healthy tissue, improving patient outcomes and reducing side effects.

3. Expansion of MR-Guided and Image-Guided Radiotherapy

Integration of real-time MRI imaging with radiation delivery, exemplified by systems like Elekta Unity and Siemens Healthineers' MR-Linac platforms, is enabling adaptive treatment that adjusts to tumor movement and anatomical changes during therapy sessions.

4. Growing Healthcare Infrastructure Investment in Emerging Markets

Expanding hospital infrastructure and healthcare access across Asia-Pacific, Latin America, and parts of the Middle East is broadening the addressable patient population for radiation therapy equipment and services.

5. Aging Global Population

Rising cancer risk with age, combined with global demographic aging trends, particularly in developed markets, is sustaining long-term structural demand for radiation oncology services and equipment.

6. AI and Software-Driven Treatment Planning

Advances in artificial intelligence and machine learning are improving the speed, accuracy, and personalization of radiation treatment planning, reducing planning time and supporting more adaptive, patient-specific therapy protocols.

Top 10 Companies in the Radiation Therapy Market

• Siemens Healthineers AG (including Varian oncology solutions)
• GE Healthcare Technologies Inc.
• Koninklijke Philips N.V. (Philips Healthcare)
• Elekta AB
• Hitachi, Ltd. (Hitachi Healthcare)
• Ion Beam Applications S.A. (IBA Worldwide)
• Accuray Incorporated
• Novartis AG (Advanced Accelerator Applications)
• Nordion, Inc.
• Mitsubishi Electric Corporation

1. Siemens Healthineers AG

2. Elekta AB

3. Accuray Incorporated

4. Ion Beam Applications S.A. (IBA Worldwide)

5. GE Healthcare Technologies Inc.

Competitive Landscape

The global radiation therapy market is highly consolidated at the top, dominated by a small number of large medical technology conglomerates alongside a handful of specialized radiation oncology pure-plays.

Consolidation Through Acquisition: Siemens Healthineers' 2021 acquisition of Varian Medical Systems, once an independent radiotherapy market leader, illustrates the sector's broader consolidation trend, in which diversified medical imaging giants absorb specialized radiation oncology technology to build comprehensive cancer care portfolios spanning diagnosis, treatment planning, and delivery.

Specialists vs. Diversified Conglomerates: Companies like Elekta, Accuray, and IBA compete as focused radiation oncology specialists, differentiating through deep technical expertise in specific modalities such as MR-guided radiotherapy, robotic radiosurgery, and proton therapy, while diversified players like Siemens Healthineers, GE Healthcare, and Philips compete on integrated imaging-to-treatment ecosystem breadth.

Proton Therapy as a Premium, High-Barrier Segment: Given the substantial capital cost of proton therapy centers, this segment remains concentrated among a small number of specialized providers like IBA and Siemens Healthineers' ProBeam platform, with high switching costs and long sales cycles favoring established players.

AI and Software as the New Differentiator: As hardware capabilities converge across major vendors, competitive differentiation is increasingly shifting toward AI-powered treatment planning software, adaptive therapy algorithms, and oncology informatics platforms that improve clinical workflow efficiency and treatment personalization.

Regional Analysis

North America

North America dominates the radiation therapy market, driven by high cancer prevalence, strong healthcare infrastructure, and early adoption of advanced therapies including proton therapy and MR-guided radiotherapy.

Europe

Europe represents a moderate-growth, mature market, supported by established healthcare systems, universal coverage models that improve treatment access, and steadily increasing cancer incidence across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by rising cancer awareness, expanding healthcare access and infrastructure investment, and increasing cancer incidence across large population centers in China, India, and Southeast Asia.

Latin America

Latin America shows moderate growth, supported by gradually improving cancer care facilities and expanding access to radiation oncology services in major urban centers.

Middle East & Africa

The Middle East & Africa region shows comparatively slower growth, constrained by limited healthcare resources and lower awareness levels, though select Gulf markets are investing in advanced cancer care infrastructure.

Emerging Trends in the Radiation Therapy Market

1. Proton and Particle Therapy Expansion: Continued investment in proton therapy technology is expanding access to this highly precise treatment modality, though its significantly higher cost, approximately USD 32,000 versus USD 18,000 for conventional therapy according to a University of Michigan analysis, remains a barrier to broader adoption.

2. MR-Guided Adaptive Radiotherapy: Real-time MRI-integrated radiation delivery systems are enabling treatment plans that adjust dynamically to tumor movement and anatomical changes during therapy, improving precision for hard-to-target tumors.

3. AI-Powered Treatment Planning: Machine learning algorithms are increasingly used to accelerate and personalize radiation treatment planning, reducing the time from diagnosis to treatment initiation.

4. Compact and More Accessible Proton Therapy Systems: Companies like IBA are developing smaller-footprint proton therapy systems aimed at lowering the capital barrier that has historically limited proton therapy to a small number of large academic medical centers.

5. Growing Radiopharmaceutical Integration: Expansion of targeted radiopharmaceutical therapies, exemplified by products from companies like Novartis's Advanced Accelerator Applications unit, is creating a complementary growth pathway alongside traditional external and internal beam radiation therapy.

Future Outlook (2025–2034)

The global radiation therapy market's trajectory toward USD 12.93 billion by 2034 reflects the durable, structural nature of cancer as a growing global health burden, with radiation therapy remaining one of the most effective and widely used treatment modalities. The 5.73% CAGR forecast through 2034 assumes continued adoption of advanced, precision-targeted techniques, sustained healthcare infrastructure investment in emerging markets, and gradual progress in reducing the cost barriers that currently limit proton therapy access.

Key investment themes include continued expansion of proton and particle therapy access through more compact and cost-efficient system designs, deeper integration of AI-powered adaptive treatment planning, and growing radiopharmaceutical therapy adoption as a complementary cancer treatment pathway. Leading companies including Siemens Healthineers, Elekta, and Accuray are likely to retain their strong market positions, while specialized providers like IBA continue to compete for share in the high-value proton therapy segment.

Frequently Asked Questions (FAQ)

1. What is the current size of the global radiation therapy market?

The global radiotherapy market was valued at approximately USD 7.86 billion in 2025 and is projected to reach USD 12.93 billion by 2034, growing at a CAGR of 5.73%.

2. Who are the top companies in the radiation therapy market?

Leading companies include Siemens Healthineers (which now includes Varian's oncology business), GE Healthcare, Philips Healthcare, Elekta, Hitachi, IBA Worldwide, Accuray, Novartis (Advanced Accelerator Applications), Nordion, and Mitsubishi Electric.

3. Which region dominates the radiation therapy market?

North America dominates the market due to high cancer prevalence, strong healthcare infrastructure, and early adoption of advanced therapies, while Asia-Pacific is expected to be the fastest-growing region.

4. What is the forecast CAGR for the radiation therapy market?

The market is forecast to grow at a CAGR of 5.73% from 2025 to 2034.

5. What are the main growth drivers for this market?

Key drivers include the rising global incidence of cancer, expected to reach 24 million cases annually by 2030 according to the WHO, and increasing adoption of advanced techniques like proton therapy that more precisely target tumors while sparing healthy tissue.

6. What challenges does the radiation therapy industry face?

The industry's primary challenge is high treatment cost, particularly for proton therapy, which can cost significantly more than conventional radiation therapy, limiting access in developing regions and among uninsured or underinsured patients.

7. What is the difference between external and internal beam radiation therapy?

External beam radiation therapy (EBRT) delivers high-energy beams from outside the body using a linear accelerator, while internal beam radiation therapy (IBRT), also known as brachytherapy, places radioactive material directly inside the body near the tumor; EBRT is the more commonly used method.

Conclusion

The global radiation therapy market sits at the intersection of rising global cancer burden and continued advancement in precision medical technology. With a projected size of USD 12.93 billion by 2034 at a 5.73% CAGR, the sector offers steady, structurally supported growth as advanced techniques like proton therapy and MR-guided radiotherapy become more accessible over time.

Siemens Healthineers now leads the market decisively following its acquisition of Varian, while specialists like Elekta, Accuray, and IBA continue to compete through deep technical focus on specific radiation oncology modalities. The companies that successfully reduce the cost and accessibility barriers facing advanced techniques like proton therapy, while continuing to integrate AI-driven treatment planning, will define market leadership through 2034 and beyond.